Display of GPI-anchored anti-EGFR nanobodies on extracellular vesicles promotes tumour cell targeting

Journal of Extracellular Vesicles

Volumn 5, Issue 1, 2016, Pages

  Kooijmans, Sander A A ^a   Aleza, Clara Gómez ^a   Roffler, Steve R ^b   van Solinge, Wouter W ^a   Vader, Pieter ^a   Schiffelers, Raymond M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

Author keywords

drug delivery; epidermal growth factor receptor; exosomes; extracellular vesicles; glycosylphosphatidylinositol anchor; lipid raft; nanobody; perfusion; targeting

Indexed keywords

DECAY ACCELERATING FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; GLYCOSYLPHOSPHATIDYLINOSITOL; NANOBODY;

ARTICLE; CELL FUNCTION; CELL INTERACTION; CELL ISOLATION; CELL SIZE; CELL STRUCTURE; CONTROLLED STUDY; ELECTRON MICROSCOPY; EXOSOME; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENETIC TRANSFECTION; HUMAN; LIVE CELL IMAGING; PROTEIN EXPRESSION; SIZE EXCLUSION CHROMATOGRAPHY; TARGET CELL; TUMOR CELL; TUMOR PROMOTION; ULTRAFILTRATION; WESTERN BLOTTING;

EID: 84978404140     PISSN: None     EISSN: 20013078     Source Type: Journal    
DOI: 10.3402/jev.v5.31053     Document Type: Article

References (65)

1. Colombo M, Raposo G, Thery C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol. 2014; 30: 255–89.
2. Yanez-Mo M, Siljander PR, Andreu Z, Zavec AB, Borras FE, Buzas EI, etal. Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles. 2015; 4: 27066, doi: http://dx.doi.org/10.3402/jev.v4.27066.
3. van Dommelen SM, Vader P, Lakhal S, Kooijmans SA, van Solinge WW, Wood MJ, etal. Microvesicles and exosomes: opportunities for cell-derived membrane vesicles in drug delivery. J Control Release. 2012; 161: 635–44.
4. Kooijmans SA, Vader P, van Dommelen SM, van Solinge WW, Schiffelers RM. Exosome mimetics: a novel class of drug delivery systems. Int J Nanomed. 2012; 7: 1525–41.
5. van der Meel R, Fens MH, Vader P, van Solinge WW, Eniola-Adefeso O, Schiffelers RM. Extracellular vesicles as drug delivery systems: lessons from the liposome field. J Control Release. 2014; 195: 72–85.
6. El-Andaloussi S, Mager I, Breakefield XO, Wood MJ. Extracellular vesicles: biology and emerging therapeutic opportunities. Nat Rev Drug Discov. 2013; 12: 347–57.
7. Fuhrmann G, Herrmann IK, Stevens MM. Cell-derived vesicles for drug therapy and diagnostics: opportunities and challenges. Nano Today. 2015; 10: 397–409.
8. Batrakova EV, Kim MS. Using exosomes, naturally-equipped nanocarriers, for drug delivery. J Control Release. 2015; 219: 396–405.
9. Gyorgy B, Hung ME, Breakefield XO, Leonard JN. Therapeutic applications of extracellular vesicles: clinical promise and open questions. Annu Rev Pharmacol Toxicol. 2015; 55: 439–64.
10. Lener T, Gimona M, Aigner L, Borger V, Buzas E, Camussi G, etal. Applying extracellular vesicles based therapeutics in clinical trials–an ISEV position paper. J Extracell Vesicles. 2015; 4: 30087, doi: http://dx.doi.org/10.3402/jev.v4.30087.
11. Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, Wood MJ. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol. 2011; 29: 341–5.
12. Tang K, Zhang Y, Zhang H, Xu P, Liu J, Ma J, etal. Delivery of chemotherapeutic drugs in tumour cell-derived microparticles. Nat Commun. 2012; 3: 1282.
13. Gujrati V, Kim S, Kim SH, Min JJ, Choy HE, Kim SC, etal. Bioengineered bacterial outer membrane vesicles as cell-specific drug-delivery vehicles for cancer therapy. ACS Nano. 2014; 8: 1525–37.
14. Ohno S, Takanashi M, Sudo K, Ueda S, Ishikawa A, Matsuyama N, etal. Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells. Mol Ther. 2013; 21: 185–91.
15. Cooper JM, Wiklander PB, Nordin JZ, Al-Shawi R, Wood MJ, Vithlani M, etal. Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice. Mov Disord. 2014; 29: 1476–85.
16. Tian Y, Li S, Song J, Ji T, Zhu M, Anderson GJ, etal. A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials. 2014; 35: 2383–90.
17. Kooijmans SAA, Fliervoet LAL, van der Meel R, Fens MHAM, Heijnen HFG, van Bergen en Henegouwen PMP, etal. PEGylated and targeted extracellular vesicles display enhanced cell specificity and circulation time. J Control Release. 2016; 224: 77–85.
18. Mulcahy LA, Pink RC, Carter DR. Routes and mechanisms of extracellular vesicle uptake. J Extracell Vesicles. 2014; 3: 24641, doi: http://dx.doi.org/10.3402/jev.v3.24641.
19. Hung ME, Leonard JN. Stabilization of exosome-targeting peptides via engineered glycosylation. J Biol Chem. 2015; 290: 8166–72.
20. Smyth T, Petrova K, Payton NM, Persaud I, Redzic JS, Graner MW, etal. Surface functionalization of exosomes using click chemistry. Bioconjug Chem. 2014; 25: 1777–84.
21. Wang M, Altinoglu S, Takeda YS, Xu Q. Integrating protein engineering and bioorthogonal click conjugation for extracellular vesicle modulation and intracellular delivery. PLoS One. 2015; 10: e0141860.
22. Wubbolts R, Leckie RS, Veenhuizen PT, Schwarzmann G, Mobius W, Hoernschemeyer J, etal. Proteomic and biochemical analyses of human B cell-derived exosomes. Potential implications for their function and multivesicular body formation. J Biol Chem. 2003; 278: 10963–72.
23. de Gassart A, Geminard C, Fevrier B, Raposo G, Vidal M. Lipid raft-associated protein sorting in exosomes. Blood. 2003; 102: 4336–44.
24. Rabesandratana H, Toutant JP, Reggio H, Vidal M. Decay-accelerating factor (CD55) and membrane inhibitor of reactive lysis (CD59) are released within exosomes during in vitro maturation of reticulocytes. Blood. 1998; 91: 2573–80.
25. Chen CP, Hsieh YT, Prijovich ZM, Chuang HY, Chen KC, Lu WC, etal. ECSTASY, an adjustable membrane-tethered/soluble protein expression system for the directed evolution of mammalian proteins. Protein Eng Des Sel. 2012; 25: 367–75.
26. Chou WC, Liao KW, Lo YC, Jiang SY, Yeh MY, Roffler SR. Expression of chimeric monomer and dimer proteins on the plasma membrane of mammalian cells. Biotechnol Bioeng. 1999; 65: 160–9.
27. Cheng TL, Roffler S. Membrane-tethered proteins for basic research, imaging, and therapy. Med Res Rev. 2008; 28: 885–928.
28. Revets H, De Baetselier P, Muyldermans S. Nanobodies as novel agents for cancer therapy. Expert Opin Biol Ther. 2005; 5: 111–24.
29. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med. 2008; 358: 1160–74.
30. Tebbutt N, Pedersen MW, Johns TG. Targeting the ERBB family in cancer: couples therapy. Nat Rev Cancer. 2013; 13: 663–73.
31. Nordin JZ, Lee Y, Vader P, Mager I, Johansson HJ, Heusermann W, etal. Ultrafiltration with size-exclusion liquid chromatography for high yield isolation of extracellular vesicles preserving intact biophysical and functional properties. Nanomedicine. 2015; 11: 879–83.
32. Heijnen HF, Schiel AE, Fijnheer R, Geuze HJ, Sixma JJ. Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha-granules. Blood. 1999; 94: 3791–9.
33. Hofman EG, Ruonala MO, Bader AN, van den Heuvel D, Voortman J, Roovers RC, etal. EGF induces coalescence of different lipid rafts. J Cell Sci. 2008; 121(Pt 15):2519–28.
34. Schmitz KR, Bagchi A, Roovers RC, van Bergen en Henegouwen PM, Ferguson KM. Structural evaluation of EGFR inhibition mechanisms for nanobodies/VHH domains. Structure. 2013; 21: 1214–24.
35. Frenken LG, van der Linden RH, Hermans PW, Bos JW, Ruuls RC, de Geus B, etal. Isolation of antigen specific llama VHH antibody fragments and their high level secretion by Saccharomyces cerevisiae. J Biotechnol. 2000; 78: 11–21.
36. Oliveira S, van Dongen GA, Stigter-van Walsum M, Roovers RC, Stam JC, Mali W, etal. Rapid visualization of human tumor xenografts through optical imaging with a near-infrared fluorescent anti-epidermal growth factor receptor nanobody. Mol Imaging. 2012; 11: 33–46.
37. van der Meel R, Oliveira S, Altintas I, Haselberg R, van der Veeken J, Roovers RC, etal. Tumor-targeted nanobullets: anti-EGFR nanobody-liposomes loaded with anti-IGF-1R kinase inhibitor for cancer treatment. J Control Release. 2012; 159: 281–9.
38. Udenfriend S, Kodukula K. How glycosylphosphatidylinositol-anchored membrane proteins are made. Annu Rev Biochem. 1995; 64: 563–91.
39. Levental I, Grzybek M, Simons K. Greasing their way: lipid modifications determine protein association with membrane rafts. Biochemistry. 2010; 49: 6305–16.
40. Thery C, Amigorena S, Raposo G, Clayton A. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol. 2006;Chapter 3:Unit 3.22.
41. Thery C, Ostrowski M, Segura E. Membrane vesicles as conveyors of immune responses. Nat Rev Immunol. 2009; 9: 581–93.
42. Li J, Lee Y, Johansson HJ, Mager I, Vader P, Nordin JZ, etal. Serum-free culture alters the quantity and protein composition of neuroblastoma-derived extracellular vesicles. J Extracell Vesicles. 2015; 4: 26883, doi: http://dx.doi.org/10.3402/jev.v4.26883.
43. Montecalvo A, Larregina AT, Shufesky WJ, Beer Stolz D, Sullivan ML, Karlsson JM, etal. Mechanism of transfer of functional microRNAs between mouse dendritic cells via exosomes. Blood. 2012; 119: 756–66.
44. Zhang F, Wang S, Yin L, Yang Y, Guan Y, Wang W, etal. Quantification of epidermal growth factor receptor expression level and binding kinetics on cell surfaces by surface plasmon resonance imaging. Anal Chem. 2015; 87: 9960–5.
45. Jain RK. Barriers to drug delivery in solid tumors. Sci Am. 1994; 271: 58–65.
46. Jain RK, Tong RT, Munn LL. Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res. 2007; 67: 2729–35.
47. Ozturk D, Yonucu S, Yilmaz D, Unlu MB. Influence of vascular normalization on interstitial flow and delivery of liposomes in tumors. Phys Med Biol. 2015; 60: 1477–96.
48. Lai CP, Mardini O, Ericsson M, Prabhakar S, Maguire CA, Chen JW, etal. Dynamic biodistribution of extracellular vesicles in vivo using a multimodal imaging reporter. ACS Nano. 2014; 8: 483–94.
49. Fevrier B, Vilette D, Archer F, Loew D, Faigle W, Vidal M, etal. Cells release prions in association with exosomes. Proc Natl Acad Sci USA. 2004; 101: 9683–8.
50. Del Conde I, Shrimpton CN, Thiagarajan P, Lopez JA. Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. Blood. 2005; 106: 1604–11.
51. Staubach S, Razawi H, Hanisch FG. Proteomics of MUC1-containing lipid rafts from plasma membranes and exosomes of human breast carcinoma cells MCF-7. Proteomics. 2009; 9: 2820–35.
52. Laulagnier K, Motta C, Hamdi S, Roy S, Fauvelle F, Pageaux JF, etal. Mast cell– and dendritic cell-derived exosomes display a specific lipid composition and an unusual membrane organization. Biochem J. 2004; 380(Pt 1):161–71.
53. Tan SS, Yin Y, Lee T, Lai RC, Yeo RW, Zhang B, etal. Therapeutic MSC exosomes are derived from lipid raft microdomains in the plasma membrane. J Extracell Vesicles. 2013; 2: 22614, doi: http://dx.doi.org/10.3402/jev.v2i0.22614.
54. Trajkovic K, Hsu C, Chiantia S, Rajendran L, Wenzel D, Wieland F, etal. Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science. 2008; 319: 1244–7.
55. Thery C, Regnault A, Garin J, Wolfers J, Zitvogel L, Ricciardi-Castagnoli P, etal. Molecular characterization of dendritic cell-derived exosomes. Selective accumulation of the heat shock protein hsc73. J Cell Biol. 1999; 147: 599–610.
56. Kroll MH, Hellums JD, McIntire LV, Schafer AI, Moake JL. Platelets and shear stress. Blood. 1996; 88: 1525–41.
57. Zech D, Rana S, Buchler MW, Zoller M. Tumor-exosomes and leukocyte activation: an ambivalent crosstalk. Cell Commun Signal. 2012; 10: 37.
58. Svensson KJ, Christianson HC, Wittrup A, Bourseau-Guilmain E, Lindqvist E, Svensson LM, etal. Exosome uptake depends on ERK1/2-heat shock protein 27 signaling and lipid Raft-mediated endocytosis negatively regulated by caveolin-1. J Biol Chem. 2013; 288: 17713–24.
59. Oliveira S, Schiffelers RM, van der Veeken J, van der Meel R, Vongpromek R, van Bergen En Henegouwen PM, etal. Downregulation of EGFR by a novel multivalent nanobody-liposome platform. J Control Release. 2010; 145: 165–75.
60. Zhong Y, Meng F, Deng C, Zhong Z. Ligand-directed active tumor-targeting polymeric nanoparticles for cancer chemotherapy. Biomacromolecules. 2014; 15: 1955–69.
61. Reuter KG, Perry JL, Kim D, Luft JC, Liu R, DeSimone JM. Targeted PRINT Hydrogels: the role of nanoparticle size and ligand density on cell association, biodistribution, and tumor accumulation. Nano Lett. 2015; 15: 6371–8.
62. Brown DA, London E. Functions of lipid rafts in biological membranes. Annu Rev Cell Dev Biol. 1998; 14: 111–36.
63. Osteikoetxea X, Sodar B, Nemeth A, Szabo-Taylor K, Paloczi K, Vukman KV, etal. Differential detergent sensitivity of extracellular vesicle subpopulations. Org Biomol Chem. 2015; 13: 9775–82.
64. Osteikoetxea X, Balogh A, Szabo-Taylor K, Nemeth A, Szabo TG, Paloczi K, etal. Improved characterization of EV preparations based on protein to lipid ratio and lipid properties. PLoS One. 2015; 10: e0121184.
65. Janas T, Janas MM, Sapon K. Mechanisms of RNA loading into exosomes. FEBS Lett. 2015; 589: 1391–8.